Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 26, 2026, 5:29 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 697–720 of 1,466 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Infection Control Clear all
Withdrawn Phase 3 Interventional Accepts healthy volunteers

A Study to Evaluate the Efficacy of Xlear vs. Placebo for Acute COVID-19 Infection

NCT04858620
View directory record Official record
Conditions
Covid19
Interventions
Xlear Nasal Spray, Placebo
Drug
Lead sponsor
Larkin Community Hospital
Other
Eligibility
18 Years to 90 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Oct 16, 2023 · Synced Oct 26, 2026, 5:29 PM EDT
Completed Phase 2Phase 3 Interventional

Study of Combivir for Patients With Primary Biliary Cirrhosis

NCT00490620
View directory record Official record
Conditions
Primary Biliary Cirrhosis
Interventions
Combination antiviral therapy, Placebo
Drug
Lead sponsor
University of Alberta
Other
Eligibility
18 Years to 75 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
2
States / cities
Rochester, Minnesota • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Nov 1, 2007 · Synced Oct 26, 2026, 5:29 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of the Safety and Pharmacokinetics of KSP-1007 Alone and Coadministered With Meropenem in Healthy Subjects

NCT05226923
View directory record Official record
Conditions
Bacterial Infections
Interventions
KSP-1007, Placebo:0.9% sodium chloride, Meropenem
Drug · Other
Lead sponsor
Sumitovant Biopharma, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
123 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Oct 27, 2022 · Synced Oct 26, 2026, 5:29 PM EDT
Recruiting Phase 2 Interventional

A Trial to Evaluate the Safety, Tolerability and Efficacy of AIC263029 in Kidney Transplant Recipients With BKV Infection

NCT07503561
View directory record Official record
Conditions
BK Virus Infection, BKV Infection, Kidney Transplant
Interventions
AIC263029, Placebo
Drug
Lead sponsor
AiCuris Anti-infective Cures AG
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
7
States / cities
Birmingham, Alabama • Tampa, Florida • Atlanta, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Oct 26, 2026, 5:29 PM EDT
Terminated Phase 4 Interventional

Procalcitonin Level to Discontinue Antibiotics on ICU Patients With no Obvious Site of Infection

NCT00407147
View directory record Official record
Conditions
Infection, Bacterial Infection, Sepsis
Interventions
Procalcitonin assay - B.R.A.H.M.S PCT sensitive Kryptor
Device
Lead sponsor
Brahms AG
Industry
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
3
States / cities
St Louis, Missouri • Camden, New Jersey • Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Jan 18, 2012 · Synced Oct 26, 2026, 5:29 PM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers

Oral Vancomycin for Secondary Prophylaxis of Clostridium Difficile Infection (CDI)

NCT04000555
View directory record Official record
Conditions
Clostridium Difficile Infection, Clostridium Difficile Infection Recurrence
Interventions
Oral Vancomycin, Placebo
Drug · Other
Lead sponsor
University of South Florida
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
2
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Apr 21, 2023 · Synced Oct 26, 2026, 5:29 PM EDT
Terminated Phase 2Phase 3 Interventional Results available

Study of Posoleucel (ALVR105,Viralym-M) for Multi-Virus Prevention in Patients Post-Allogeneic Hematopoietic Cell Transplant

NCT05305040
View directory record Official record
Conditions
Adenovirus Infection, BK Virus Infection, Cytomegalovirus Infections, Epstein-Barr Virus Infections, Human Herpes Virus-6 Infection, JC Virus Infection
Interventions
Posoleucel (ALVR105), Placebo
Biological
Lead sponsor
AlloVir
Industry
Eligibility
Not listed
Enrollment
451 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
35
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Duarte, California + 31 more
Source: ClinicalTrials.gov public record
Updated May 16, 2024 · Synced Oct 26, 2026, 5:29 PM EDT
Completed Phase 2 Interventional Results available

Safety and Tolerability Study of 2 Dose Level of Arikayce™ in Patients With Bronchiectasis and Chronic Infection Due to Pseudomonas Aeruginosa.

NCT00775138
View directory record Official record
Conditions
Bronchiectasis
Interventions
280 mg Arikayce™, Matching Placebo for Cohort 1, 560 mg Arikayce™, Matching Placebo for Cohort 2
Drug
Lead sponsor
Insmed Incorporated
Industry
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 10, 2019 · Synced Oct 26, 2026, 5:29 PM EDT
Withdrawn No phase listed Observational

2009 H1N1 Pandemic and Seasonal Influenza in SCI/D: Infection Control Strategies

NCT01270685
View directory record Official record
Conditions
Influenza
Interventions
Not listed
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years to 89 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Hines, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 26, 2015 · Synced Oct 26, 2026, 5:29 PM EDT
Completed Phase 2 Interventional Results available

Respiratory Syncytial Virus - RSV Protocol

NCT01502072
View directory record Official record
Conditions
Bone Marrow Transplant Infection, Infection in Marrow Transplant Recipients, Respiratory Syncytial Virus Infections, Respiratory Syncytial Virus Pneumonia, Cancer, Acute Leukemia
Interventions
Ribavirin
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 15, 2021 · Synced Oct 26, 2026, 5:29 PM EDT
Terminated Not applicable Interventional

Acupuncture and Post-Surgical Wound Healing

NCT00260494
View directory record Official record
Conditions
Postoperative Complications, Surgical Wound Infection, Surgical Wound Dehiscence
Interventions
acupuncture, sham acupuncture
Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 23, 2013 · Synced Oct 26, 2026, 5:29 PM EDT
Terminated Phase 3 Interventional Accepts healthy volunteers Results available

Oral ISL QM as PrEP in Cisgender Women at High Risk for HIV-1 Infection (MK-8591-022)

NCT04644029
View directory record Official record
Conditions
HIV-I, Human Immunodeficiency Virus Type 1, Prophylaxis
Interventions
Islatravir, Placebo to FTC/TDF, FTC/TDF, Placebo to ISL
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
16 Years to 45 Years · Female only
Enrollment
730 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
13
States / cities
Birmingham, Alabama • Washington D.C., District of Columbia • Miami, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Oct 26, 2026, 5:29 PM EDT
Terminated Phase 2 Interventional Results available

Safety and Efficacy of Melatonin in Outpatients Infected With COVID-19

NCT04474483
View directory record Official record
Conditions
COVID-19
Interventions
Melatonin, Placebo (Methylcellulose) capsule
Drug · Other
Lead sponsor
State University of New York at Buffalo
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Feb 7, 2024 · Synced Oct 26, 2026, 5:29 PM EDT
Completed Phase 1Phase 2 Interventional

Study of Safety, Tolerability, and Anti-Viral Effect of Locteron Compared to PEG-Intron in Patients With Chronic Hepatitis C

NCT00593151
View directory record Official record
Conditions
Hepatitis C
Interventions
Locteron (controlled-release interferon alpha 2b), pegylated IFNa2b
Other · Biological
Lead sponsor
Biolex Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
5
States / cities
Detroit, Michigan • Dallas, Texas • San Antonio, Texas + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2012 · Synced Oct 26, 2026, 5:29 PM EDT
Completed Phase 2 Interventional

A Study of Ridinilazole (SMT19969) Compared With Fidaxomicin for the Treatment of Clostridium Difficile Infection (CDI)

NCT02784002
View directory record Official record
Conditions
Clostridium Difficile Infection
Interventions
Ridinilazole, Fidaxomicin
Drug
Lead sponsor
Summit Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
5
States / cities
Laguna Hills, California • Ventura, California • Idaho Falls, Idaho + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 12, 2017 · Synced Oct 26, 2026, 5:29 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Vaginal Cleansing Before Cesarean Delivery to Reduce Infection

NCT02495753
View directory record Official record
Conditions
Complications; Cesarean Section
Interventions
Vaginal Cleansing, Abdominal Cleansing
Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
Female only
Enrollment
608 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2021
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 6, 2021 · Synced Oct 26, 2026, 5:29 PM EDT
Completed Phase 3 Interventional Results available

Treatment of Chlamydia Infection Comparing WC2031 Tablets With Vibramycin

NCT01113931
View directory record Official record
Conditions
Urogential Chlamydia Trachomatis Infection
Interventions
Doxycyline Hyclate tablet, Vibramycin (doxycyline hyclate) capsule
Drug
Lead sponsor
Warner Chilcott
Industry
Eligibility
19 Years to 45 Years
Enrollment
495 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
43
States / cities
Birmingham, Alabama • Foley, Alabama • Tucson, Arizona + 38 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2012 · Synced Oct 26, 2026, 5:29 PM EDT
Completed Phase 3 Interventional Results available

Suprachoroidal Injection of CLS-TA in Subjects With Macular Edema Associated With Non-infectious Uveitis

NCT02595398
View directory record Official record
Conditions
Uveitis, Uveitis, Posterior, Uveitis, Anterior, Uveitis, Intermediate, Panuveitis
Interventions
4mg CLS-TA Suprachoriodal Injection, Sham Procedure
Drug
Lead sponsor
Clearside Biomedical, Inc.
Industry
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
40
States / cities
Phoenix, Arizona • Tucson, Arizona • Bakersfield, California + 36 more
Source: ClinicalTrials.gov public record
Updated May 28, 2021 · Synced Oct 26, 2026, 5:29 PM EDT
Completed Not applicable Interventional

The Utility of Urinalysis Prior to In-Office Procedures

NCT03526484
View directory record Official record
Conditions
Urinary Tract Infections
Interventions
Standard of Care, Experimental
Behavioral
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
664 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
2
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 2, 2021 · Synced Oct 26, 2026, 5:29 PM EDT
Completed Phase 3 Interventional Results available

Ethanol Lock Therapy for Treatment and Secondary Prophylaxis of Central Line-Associated Bloodstream Infection

NCT01472965
View directory record Official record
Conditions
Central Line-Associated Bloodstream Infection
Interventions
ethanol, heparin-saline placebo
Drug
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
6 Months to 25 Years
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 13, 2017 · Synced Oct 26, 2026, 5:29 PM EDT
Terminated Phase 2 Interventional

Xylitol BSI Multisite - Reduction of Bloodstream Infections From Oral Organisms in Pediatric Stem Cell Transplant

NCT05579639
View directory record Official record
Conditions
Allogeneic Stem Cell Transplantation
Interventions
Xylitol, Placebo
Other
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
4 Months to 25 Years
Enrollment
256 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
3
States / cities
Aurora, Colorado • Boston, Massachusetts • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 26, 2026, 5:29 PM EDT
Terminated Phase 4 Interventional Results available

Ceftolozane-Tazobactam for Directed Treatment of Pseudomonas Aeruginosa Bacteremia and Pneumonia in Patients With Hematological Malignancies and Hematopoietic Stem Cell Transplantation

NCT04673175
View directory record Official record
Conditions
Pneumonia, Hematologic Malignancy, Pseudomonas Aeruginosa Infection, Bacteremia, Hematopoietic Stem Cell Transplant (HSCT)
Interventions
Ceftolozane / Tazobactam Injection
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced Oct 26, 2026, 5:29 PM EDT
Completed Phase 2 Interventional

A Study Comparing 4 Doses Of GW810781 Versus Placebo In HIV-Infected Patients

NCT00046332
View directory record Official record
Conditions
HIV Infections
Interventions
GW810781
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
23
States / cities
Phoenix, Arizona • Los Angeles, California • San Diego, California + 18 more
Source: ClinicalTrials.gov public record
Updated Feb 21, 2013 · Synced Oct 26, 2026, 5:29 PM EDT